Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Inventory Turnover
- The inventory turnover ratio exhibits a consistent downward trend over the analyzed periods. Starting from a high of 9.32 in early 2019, it declines steadily to around 3.59-3.89 in 2023, indicating slower inventory movement and potentially increased inventory holding.
- Receivables Turnover
- Receivables turnover remains relatively stable with modest fluctuations. It hovers around the 4.3 to 4.5 range for most of the periods, with a notable dip in late 2020 before recovering. This suggests consistent efficiency in collecting receivables.
- Payables Turnover
- Payables turnover sees substantial variability. It peaks in late 2019 and again in recent quarters of 2023, reaching above 10. This volatility could reflect changes in payment policies or negotiation terms with suppliers, with acceleration in payment at certain times and delays at others.
- Working Capital Turnover
- Working capital turnover shows considerable fluctuation. It spikes significantly in mid-2020 and mid-2023, exceeding 10, but the overall pattern does not indicate stable improvement or decline, pointing to variable efficiency in using working capital to generate revenue.
- Average Inventory Processing Period
- The average inventory processing period is on an upward trajectory, increasing from approximately 39 days in early 2019 to over 100 days in 2023. This signals longer holding times for inventory, possibly indicating slower sales or overstocking issues.
- Average Receivable Collection Period
- Receivable collection periods are largely steady, varying between approximately 80 and 90 days, with minor short-term deviations. This stability suggests consistent credit policies and collection effectiveness over time.
- Operating Cycle
- The operating cycle lengthens progressively over the periods, moving from around 120 days in early 2019 to near 190-196 days in the latest data. This indicates increasing time taken to convert inventory and receivables into cash, which could impact liquidity.
- Average Payables Payment Period
- This metric displays significant variation, decreasing from about 45 days in early 2019 to a low of approximately 32 days in late 2023 after some peaks above 90 days. These shifts suggest changes in supplier payment strategies or cash management adjustments.
- Cash Conversion Cycle
- The cash conversion cycle demonstrates a general increasing trend, rising from around 75 days in early 2019 to peaks exceeding 140 days in recent years. Despite some declines in mid periods, the extended duration implies more capital is tied up in operations, which may affect overall cash flow efficiency.
Turnover Ratios
Average No. Days
Inventory Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Cost of net revenues | 297,138) | 288,564) | 282,493) | 283,814) | 271,179) | 281,994) | 263,873) | 286,536) | 260,750) | 252,270) | 217,673) | 224,057) | 200,056) | 127,986) | 156,607) | 177,829) | 169,787) | 168,408) | 146,875) | 150,924) | 133,508) | 124,677) | 109,516) | |||||||
Inventories | 296,189) | 312,736) | 311,885) | 338,752) | 320,903) | 310,046) | 275,669) | 230,230) | 207,116) | 178,751) | 150,643) | 139,237) | 123,093) | 131,276) | 120,977) | 112,051) | 94,795) | 81,124) | 68,489) | 55,641) | 48,858) | 47,252) | 35,866) | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Inventory turnover1 | 3.89 | 3.60 | 3.59 | 3.25 | 3.44 | 3.53 | 3.86 | 4.42 | 4.61 | 5.00 | 5.11 | 5.09 | 5.38 | 4.82 | 5.56 | 5.92 | 6.71 | 7.39 | 8.12 | 9.32 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 2.71 | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | 3.59 | 3.47 | 3.27 | 2.99 | 2.99 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 1.99 | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | 2.98 | 2.90 | 2.84 | 2.64 | 2.49 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 1.92 | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | 2.43 | 2.24 | 2.20 | 2.10 | 2.23 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Inventory turnover
= (Cost of net revenuesQ3 2023
+ Cost of net revenuesQ2 2023
+ Cost of net revenuesQ1 2023
+ Cost of net revenuesQ4 2022)
÷ Inventories
= (297,138 + 288,564 + 282,493 + 283,814)
÷ 296,189 = 3.89
2 Click competitor name to see calculations.
- Cost of Net Revenues
- The cost of net revenues shows an overall increasing trend from March 31, 2018, through September 30, 2023. Initially, it rose steadily from approximately $109.5 million to $177.8 million by December 31, 2019, with some fluctuations thereafter. During 2020, despite the challenges likely posed by the global environment, the cost exhibited a significant increase, peaking around $224 million at the end of 2020 and continuing upward to reach nearly $297 million by the third quarter of 2023. The growth rate appears to accelerate notably starting in 2020, peaking in 2021 and extending into 2023 with some minor short-term volatility.
- Inventories
- Inventories have shown consistent growth over the analyzed periods, beginning at roughly $35.9 million in March 2018 and expanding significantly to nearly $296.2 million by September 2023. This represents an almost eightfold increase over the span. The increase is relatively smooth, with marked steps upward in 2019 and continuing sharply through 2022, indicating increasing stock levels. The inventory buildup accelerates in the periods beyond 2019, peaking in late 2022 and showing some signs of plateau or mild reduction within 2023.
- Inventory Turnover
- Inventory turnover exhibits a clear downward trend throughout the examined period. Starting with higher turnover ratios above 9.3 in early 2019, the ratio steadily decreases quarter over quarter, reaching around 3.6 by the end of the third quarter of 2023. The reduction in inventory turnover suggests that inventory is being replenished or held longer relative to sales, aligning with the rising inventory values noted concurrently. The decline is consistent and relatively smooth, indicating an ongoing shift in inventory management or sales patterns over the years.
- Overall Insights
- The dataset reveals a consistent increase in both the cost of net revenues and inventories, accompanied by a marked decrease in inventory turnover. This combination suggests that while sales or production costs have been growing, the company is holding more inventory relative to its sales, resulting in slower inventory movement. The increase in inventory levels combined with decreasing turnover ratios may imply potential challenges in inventory management or changing market or supply chain conditions leading to stock accumulation. The trends from 2020 onwards are particularly pronounced, reflecting possibly external factors affecting operations, such as demand fluctuations or supply chain disruptions. Overall, the financial data indicates expansion alongside increased inventory holding periods.
Receivables Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Net revenues | 960,214) | 1,002,173) | 943,147) | 901,515) | 890,348) | 969,553) | 973,219) | 1,031,099) | 1,015,906) | 1,010,808) | 894,771) | 834,520) | 734,144) | 352,314) | 550,963) | 649,787) | 607,341) | 600,697) | 548,971) | 534,020) | 505,289) | 490,259) | 436,924) | |||||||
Accounts receivable, net of allowance for doubtful accounts | 904,178) | 908,395) | 884,430) | 859,685) | 859,629) | 931,854) | 950,892) | 897,198) | 855,037) | 808,079) | 718,957) | 657,704) | 626,046) | 473,314) | 533,004) | 550,291) | 531,816) | 520,094) | 479,281) | 439,009) | 420,276) | 374,371) | 361,459) | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Receivables turnover1 | 4.21 | 4.11 | 4.19 | 4.34 | 4.50 | 4.28 | 4.24 | 4.41 | 4.39 | 4.30 | 3.92 | 3.76 | 3.65 | 4.56 | 4.52 | 4.37 | 4.31 | 4.21 | 4.34 | 4.48 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | 6.64 | 6.61 | 6.58 | 6.13 | 5.40 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | 20.66 | 18.93 | 18.81 | 17.39 | 19.72 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | 7.30 | 7.90 | 7.38 | 6.96 | 6.75 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | 5.51 | 5.35 | 5.21 | 5.73 | 6.22 | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | 20.07 | 19.60 | 18.53 | 16.35 | 19.86 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Receivables turnover
= (Net revenuesQ3 2023
+ Net revenuesQ2 2023
+ Net revenuesQ1 2023
+ Net revenuesQ4 2022)
÷ Accounts receivable, net of allowance for doubtful accounts
= (960,214 + 1,002,173 + 943,147 + 901,515)
÷ 904,178 = 4.21
2 Click competitor name to see calculations.
- Net Revenues
- Net revenues demonstrated a general upward trend from March 2018 through December 2021, with values increasing from approximately $437 million to over $1 billion. Significant growth phases are observed between 2019 and 2021, particularly a sharp rise in the last quarter of 2020 and throughout 2021. However, starting from March 2022, revenues exhibited volatility and a decline phase, with fluctuations but no return to the peak levels of 2021. Quarterly revenues ranged from about $973 million to $901 million through 2022 and 2023, suggesting some pressure or market fluctuations during this period.
- Accounts Receivable, Net of Allowance for Doubtful Accounts
- The accounts receivable balance showed a steady increase over the period analyzed, beginning at approximately $361 million in March 2018 and reaching above $900 million by late 2022 and 2023. This continuous growth in receivables aligns with the overall growth in net revenues through 2021. In 2022 and 2023, while revenues declined or stabilized at lower levels, accounts receivable remained relatively high and stable, indicating potential elongation in collection periods or changes in credit policies.
- Receivables Turnover Ratio
- The receivables turnover ratio generally fluctuated between 3.65 and 4.56 over the periods with available data, indicating how effectively the company converted its receivables into cash. Early in the dataset (2019), the ratio slightly decreased from 4.48 to about 4.21, then improved in late 2019 and early 2020 with values around 4.37 to 4.56. With the onset of 2020 and beyond, the ratio declined to a low of 3.65, reflecting slower collections, but gradually improved through 2021 to levels over 4.3. From 2022 into 2023, the turnover ratio fluctuated modestly around 4.2, suggesting relatively stable receivables management despite revenue volatility.
- Overall Financial Trends
- The analysis indicates a strong revenue growth period through 2021 accompanied by an increase in accounts receivable, consistent with expanding business. The receivables turnover ratio’s variations suggest some episodic challenges in collections, particularly around early 2020, possibly due to external factors. The slowing revenue trend starting in 2022, paired with sustained high receivables, may indicate changing market conditions or credit practices, warranting attention to cash flow management and credit risk controls moving forward.
Payables Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Cost of net revenues | 297,138) | 288,564) | 282,493) | 283,814) | 271,179) | 281,994) | 263,873) | 286,536) | 260,750) | 252,270) | 217,673) | 224,057) | 200,056) | 127,986) | 156,607) | 177,829) | 169,787) | 168,408) | 146,875) | 150,924) | 133,508) | 124,677) | 109,516) | |||||||
Accounts payable | 99,693) | 110,155) | 130,561) | 127,870) | 138,918) | 145,607) | 186,509) | 163,886) | 174,916) | 225,079) | 124,298) | 142,132) | 119,184) | 94,987) | 72,690) | 87,250) | 63,300) | 61,950) | 62,512) | 64,256) | 43,065) | 48,744) | 41,881) | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Payables turnover1 | 11.56 | 10.22 | 8.57 | 8.61 | 7.94 | 7.51 | 5.70 | 6.21 | 5.46 | 3.97 | 6.19 | 4.99 | 5.56 | 6.66 | 9.25 | 7.60 | 10.05 | 9.68 | 8.89 | 8.07 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | 4.21 | 4.55 | 4.43 | 3.97 | 3.80 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | 7.59 | 7.31 | 7.30 | 7.31 | 7.75 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | 14.45 | 14.13 | 13.71 | 14.80 | 18.35 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | 4.98 | 5.56 | 5.19 | 5.56 | 4.72 | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | 7.63 | 6.98 | 6.97 | 6.58 | 7.29 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Payables turnover
= (Cost of net revenuesQ3 2023
+ Cost of net revenuesQ2 2023
+ Cost of net revenuesQ1 2023
+ Cost of net revenuesQ4 2022)
÷ Accounts payable
= (297,138 + 288,564 + 282,493 + 283,814)
÷ 99,693 = 11.56
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the analyzed quarters. Cost of net revenues demonstrates an overall upward trajectory, escalating from approximately 109.5 million US dollars in the first quarter of 2018 to nearly 297.1 million US dollars by the third quarter of 2023. Despite some fluctuations, such as a dip around mid-2020 followed by a sharp rebound towards the end of 2020 and continuing increases thereafter, the general pattern indicates increasing operational costs aligned with possibly higher sales volumes or raw material price changes.
Accounts payable figures also show a dynamic pattern, starting at about 41.9 million US dollars at the beginning of 2018 and rising to a peak exceeding 225 million US dollars in mid-2021. Following this peak, a decline is observed, with payables reducing to nearly 99.7 million US dollars by the third quarter of 2023. This suggests periods of both increased credit purchasing activity and subsequent tightening or payment acceleration.
Regarding payables turnover ratio, the data reflects variations with an initial value around 8.07 in late 2018 dropping as low as 3.97 in mid-2021. Thereafter, a significant upward trend is observed, reaching 11.56 by the third quarter of 2023. The increase in turnover ratio in recent periods implies more efficient management of accounts payable, possibly through faster payment cycles or improved supplier negotiations.
- Cost of Net Revenues
- Demonstrates a steady increase overall, with fluctuations corresponding to specific quarters. The peak values toward 2023 indicate rising operational expenses or expansion.
- Accounts Payable
- Displays growth until mid-2021, followed by a consistent decline, suggesting shifting payment strategies or changes in credit terms with suppliers.
- Payables Turnover Ratio
- Varies significantly but shows a marked improvement in payable turnover efficiency from mid-2021 onward, indicating quicker payment cycles or optimized payable management.
Working Capital Turnover
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
Current assets | 2,701,804) | 2,465,456) | 2,331,882) | 2,424,391) | 2,500,580) | 2,376,804) | 2,480,768) | 2,494,075) | 2,455,307) | 2,231,825) | 2,115,555) | 1,849,538) | 1,473,247) | 1,149,244) | 1,576,525) | 1,633,419) | 1,505,579) | 1,457,374) | 1,439,113) | 1,302,479) | 1,224,182) | 1,260,999) | 1,168,776) | |||||||
Less: Current liabilities | 2,122,986) | 2,107,065) | 2,004,598) | 1,925,887) | 1,809,403) | 1,804,414) | 1,863,647) | 1,924,071) | 1,790,315) | 1,696,581) | 1,393,842) | 1,325,601) | 1,121,794) | 941,592) | 910,686) | 970,970) | 870,144) | 789,046) | 804,884) | 692,073) | 618,209) | 566,646) | 517,985) | |||||||
Working capital | 578,818) | 358,391) | 327,284) | 498,504) | 691,177) | 572,390) | 617,121) | 570,004) | 664,992) | 535,244) | 721,713) | 523,937) | 351,453) | 207,652) | 665,839) | 662,449) | 635,435) | 668,328) | 634,229) | 610,406) | 605,973) | 694,353) | 650,791) | |||||||
Net revenues | 960,214) | 1,002,173) | 943,147) | 901,515) | 890,348) | 969,553) | 973,219) | 1,031,099) | 1,015,906) | 1,010,808) | 894,771) | 834,520) | 734,144) | 352,314) | 550,963) | 649,787) | 607,341) | 600,697) | 548,971) | 534,020) | 505,289) | 490,259) | 436,924) | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Working capital turnover1 | 6.58 | 10.43 | 11.32 | 7.49 | 5.59 | 6.97 | 6.53 | 6.93 | 5.65 | 6.49 | 3.90 | 4.72 | 6.51 | 10.40 | 3.62 | 3.63 | 3.61 | 3.28 | 3.28 | 3.22 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | 4.06 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | 7.23 | 6.79 | 6.67 | 5.38 | 6.39 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | 1.22 | 1.17 | 1.03 | 0.88 | 0.77 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | 2.15 | 2.02 | 2.00 | 2.44 | 2.48 | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Working capital turnover
= (Net revenuesQ3 2023
+ Net revenuesQ2 2023
+ Net revenuesQ1 2023
+ Net revenuesQ4 2022)
÷ Working capital
= (960,214 + 1,002,173 + 943,147 + 901,515)
÷ 578,818 = 6.58
2 Click competitor name to see calculations.
- Working Capital
- The working capital exhibited notable fluctuations over the analyzed periods. Initially, it showed a relatively stable trend around the mid-600,000s (in thousands of US dollars) until the end of 2019. However, a significant decline occurred in early 2020, with a drop to approximately 207,652, marking a low point. Subsequent quarters witnessed a steady recovery, climbing back over 700,000 by the first quarter of 2021. After this peak, the working capital showed volatility, fluctuating between roughly 327,000 and 691,000 with no consistent upward or downward trend observed through the end of the period. This variability suggests possible operational or liquidity adjustments during these later quarters.
- Net Revenues
- Net revenues demonstrated an overall upward trajectory from early 2018 through late 2021, increasing from approximately 437,000 to above 1,031,000 (in thousands of US dollars). This growth highlights a continued improvement in sales or service income during this phase. Notably, revenues peaked around the fourth quarter of 2021 at over 1,000,000, followed by some decline and volatility in 2022 and 2023, with revenues oscillating between about 890,000 and 1,002,000. Despite these fluctuations, the revenue figures remained substantially higher than the early years, indicating sustained business expansion compared to the start of the period.
- Working Capital Turnover Ratio
- The working capital turnover ratio was only available starting from March 31, 2019. It initially maintained consistent levels around 3.2 to 3.6, indicating moderate efficiency in using working capital to generate revenues. In early 2020, there was a sharp spike, reaching about 10.4, followed by a general decline but still fluctuating at elevated levels between approximately 3.9 and 7.5 thereafter. Several peaks exceeding 10 occurred again in mid-2023. This volatility and rise may reflect significant changes in operational efficiency or shifts in either working capital management or revenue realization, especially during the period around the 2020 drop in working capital. Elevated turnover ratios suggest improved usage efficiency of working capital to generate sales, though the instability points to potential underlying cash flow or inventory management challenges.
- Summary Insight
- Overall, the data indicates a period of growth in net revenues accompanied by significant instability in working capital levels, particularly during 2020. A recovery in working capital followed, though without reclaiming consistency. The working capital turnover ratio's increase and volatility further emphasize changing operational dynamics that likely correspond to a strategic or market response to external conditions. These patterns suggest careful scrutiny of liquidity and capital management practices is warranted to maintain operational stability alongside revenue growth.
Average Inventory Processing Period
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Inventory turnover | 3.89 | 3.60 | 3.59 | 3.25 | 3.44 | 3.53 | 3.86 | 4.42 | 4.61 | 5.00 | 5.11 | 5.09 | 5.38 | 4.82 | 5.56 | 5.92 | 6.71 | 7.39 | 8.12 | 9.32 | — | — | — | |||||||
Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
Average inventory processing period1 | 94 | 101 | 102 | 112 | 106 | 104 | 95 | 83 | 79 | 73 | 71 | 72 | 68 | 76 | 66 | 62 | 54 | 49 | 45 | 39 | — | — | — | |||||||
Benchmarks (no. days) | ||||||||||||||||||||||||||||||
Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 135 | 139 | 132 | 118 | 108 | 113 | 109 | 102 | 105 | 111 | 122 | 122 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 183 | 166 | 162 | 161 | 155 | 139 | 130 | 122 | 126 | 129 | 138 | 147 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 190 | 183 | 174 | 166 | 161 | 153 | 148 | 150 | 163 | 166 | 174 | 164 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.89 = 94
2 Click competitor name to see calculations.
- Inventory Turnover
- The inventory turnover ratio shows a consistent declining trend from March 31, 2018 onwards. Initially recorded at 9.32, the ratio progressively decreased over the years, reaching figures below 6 by March 2020. This declining pattern continued steadily until it reached the lowest point of 3.25 at March 31, 2023, before showing a slight improvement to 3.89 by September 30, 2023. The overall decrease suggests that inventory is being sold and replaced less frequently over time.
- Average Inventory Processing Period
- The average inventory processing period exhibits an inverse trend relative to inventory turnover. Starting at 39 days in March 31, 2018, the number of days required to process inventory increased with some fluctuations throughout the periods. It rose sharply after 2018, reaching above 60 days by early 2020, and continued to extend to a peak of 112 days at March 31, 2023. Thereafter, there was a reduction to 94 days by September 30, 2023. These values indicate a lengthening time for inventory to move through the company, potentially reflecting slower sales or changes in inventory management.
- Overall Insights
- The data depicts a clear pattern of reduced efficiency in inventory management over the span of nearly six years. The declining inventory turnover ratio combined with increased average inventory days suggests the company faced challenges in maintaining fast-moving inventory levels. This trend could imply a buildup of stock or slower sales cycles. The recent slight reversal in both metrics by mid to late 2023 could indicate initial signs of improved turnover efficiency or inventory control, though the values remain significantly lower and higher, respectively, than those observed in earlier periods.
Average Receivable Collection Period
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Receivables turnover | 4.21 | 4.11 | 4.19 | 4.34 | 4.50 | 4.28 | 4.24 | 4.41 | 4.39 | 4.30 | 3.92 | 3.76 | 3.65 | 4.56 | 4.52 | 4.37 | 4.31 | 4.21 | 4.34 | 4.48 | — | — | — | |||||||
Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
Average receivable collection period1 | 87 | 89 | 87 | 84 | 81 | 85 | 86 | 83 | 83 | 85 | 93 | 97 | 100 | 80 | 81 | 83 | 85 | 87 | 84 | 81 | — | — | — | |||||||
Benchmarks (no. days) | ||||||||||||||||||||||||||||||
Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 59 | 56 | 53 | 52 | 52 | 58 | 59 | 55 | 55 | 55 | 60 | 68 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 20 | 19 | 22 | 19 | 19 | 19 | 22 | 18 | 19 | 19 | 21 | 19 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 51 | 50 | 53 | 55 | 51 | 51 | 56 | 50 | 46 | 49 | 52 | 54 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 70 | 67 | 62 | 64 | 63 | 63 | 63 | 66 | 68 | 70 | 64 | 59 | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 21 | 19 | 25 | 20 | 20 | 22 | 23 | 18 | 19 | 20 | 22 | 18 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.21 = 87
2 Click competitor name to see calculations.
- Receivables Turnover
- The receivables turnover ratio demonstrates some fluctuations over the observed periods. Starting in the first quarter of 2019, the ratio gradually declined from 4.48 to 4.21 by the third quarter of 2019, followed by a slight recovery to 4.31 by the end of 2019. In 2020, the ratio initially increased, reaching 4.56 in the third quarter, yet saw a significant drop to 3.65 in the fourth quarter. Throughout 2021, the turnover improved steadily, stabilizing around 4.3 to 4.41. In 2022, the ratio maintained relative consistency, predominantly in the range of 4.24 to 4.5, before a minor decline in early 2023 to approximately 4.11, later slightly increasing to 4.21 by the third quarter. Overall, the receivables turnover exhibits moderate volatility, with periods of both decline and recovery, indicating varying efficiency in collecting receivables.
- Average Receivable Collection Period
- The average receivable collection period inversely reflects the trends seen in the turnover ratio, consistent with the expected relationship between these metrics. Beginning in early 2019, the collection period increased from 81 days to a peak of 87 days by the third quarter, before slightly improving to 85 days at year-end. In 2020, the number of days grew notably, reaching 100 days in the fourth quarter, signaling slower collection. This was followed by a gradual improvement throughout 2021, reducing days to around 83-85. The period remained relatively stable and slightly improved overall in 2022, mostly fluctuating between 81 and 86 days. In 2023, there was a minor uptick again, with days increasing to 89 in the third quarter, indicating a modest slowdown in collections. The data reveals periods of extended collection times during 2020, likely reflecting external challenges, but a subsequent return towards more efficient collections in following years, albeit with some variability.
Operating Cycle
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Average inventory processing period | 94 | 101 | 102 | 112 | 106 | 104 | 95 | 83 | 79 | 73 | 71 | 72 | 68 | 76 | 66 | 62 | 54 | 49 | 45 | 39 | — | — | — | |||||||
Average receivable collection period | 87 | 89 | 87 | 84 | 81 | 85 | 86 | 83 | 83 | 85 | 93 | 97 | 100 | 80 | 81 | 83 | 85 | 87 | 84 | 81 | — | — | — | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Operating cycle1 | 181 | 190 | 189 | 196 | 187 | 189 | 181 | 166 | 162 | 158 | 164 | 169 | 168 | 156 | 147 | 145 | 139 | 136 | 129 | 120 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 194 | 195 | 185 | 170 | 160 | 171 | 168 | 157 | 160 | 166 | 182 | 190 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 234 | 216 | 215 | 216 | 206 | 190 | 186 | 172 | 172 | 178 | 190 | 201 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 260 | 250 | 236 | 230 | 224 | 216 | 211 | 216 | 231 | 236 | 238 | 223 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 94 + 87 = 181
2 Click competitor name to see calculations.
The analysis of the quarterly financial periods reveals notable trends in the management of inventory, receivables, and overall operating cycle durations over time.
- Average Inventory Processing Period
-
The inventory processing period shows a clear increasing trend from 39 days in March 2019 to a peak of 112 days in March 2023, indicating a lengthening time for inventory turnover. Notably, there is a steady rise with some fluctuations, achieving the highest values in the period between mid-2022 and early 2023, before slightly decreasing to 94 days by September 2023. This suggests potential challenges in inventory management or changes in supply chain dynamics.
- Average Receivable Collection Period
-
The receivable collection period demonstrates more stability compared to inventory, fluctuating mostly between 80 and 100 days throughout the periods analyzed. It peaked at 100 days in December 2020 but generally maintains a range in the mid-80s towards the latest quarters. The relative consistency suggests stable credit policies and collection efficiency, with minor variations that might be influenced by external or market factors.
- Operating Cycle
-
The operating cycle, combining inventory and receivable periods, shows a consistent upward trend from 120 days in March 2019 to a high of 196 days in March 2023. This indicates an overall elongation in the cash conversion cycle, primarily driven by the increase in inventory processing days. Although some minor declines occur, the trend implies increasing capital tied up in working capital.
In summary, the data reflects a growing duration to process inventory and complete the full operating cycle, while receivables collection remains relatively stable. The stretched operating cycle could signal the necessity for the company to review its inventory management and working capital efficiency to improve liquidity and operational performance.
Average Payables Payment Period
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Payables turnover | 11.56 | 10.22 | 8.57 | 8.61 | 7.94 | 7.51 | 5.70 | 6.21 | 5.46 | 3.97 | 6.19 | 4.99 | 5.56 | 6.66 | 9.25 | 7.60 | 10.05 | 9.68 | 8.89 | 8.07 | — | — | — | |||||||
Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
Average payables payment period1 | 32 | 36 | 43 | 42 | 46 | 49 | 64 | 59 | 67 | 92 | 59 | 73 | 66 | 55 | 39 | 48 | 36 | 38 | 41 | 45 | — | — | — | |||||||
Benchmarks (no. days) | ||||||||||||||||||||||||||||||
Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 80 | 85 | 82 | 88 | 78 | 86 | 91 | 87 | 80 | 82 | 92 | 96 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Elevance Health Inc. | 48 | 48 | 48 | 49 | 49 | 50 | 50 | 48 | 50 | 50 | 50 | 47 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 31 | 33 | 28 | 26 | 30 | 29 | 25 | 25 | 26 | 27 | 25 | 20 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 78 | 79 | 79 | 82 | 71 | 67 | 64 | 73 | 66 | 70 | 66 | 77 | — | — | — | — | — | — | — | — | — | — | — | |||||||
UnitedHealth Group Inc. | 51 | 52 | 53 | 50 | 52 | 53 | 54 | 48 | 52 | 52 | 56 | 50 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 11.56 = 32
2 Click competitor name to see calculations.
- Payables Turnover Ratio
- The payables turnover ratio exhibits an overall upward trend from the initial recorded period in March 2018 to September 2023. Starting at 8.07 in March 2018, the ratio increased steadily, reaching a peak of 10.22 by March 2023, and further rising to 11.56 in September 2023. Despite some fluctuations, including a notable dip to 3.97 in September 2021, the general direction indicates enhanced ability to pay off suppliers, suggesting improved operational efficiency and cash management over time.
- Average Payables Payment Period
- The average payables payment period, measured in days, shows an inverse relationship with the payables turnover ratio, as expected. From March 2018 through September 2023, this period generally decreased, signifying faster payments to suppliers. For instance, it was 45 days in March 2018, extending to its highest at 92 days in September 2021, which corresponds with the lowest payables turnover ratio during the same period. After this peak, the payment period notably declined to 32 days by September 2023, indicating an accelerated payment cycle consistent with the upward trend in the payables turnover ratio.
- Insights and Patterns
- The data reveals that the company has managed to shorten its payment terms to suppliers especially after a temporary extension in 2021. This shift could indicate improved liquidity and a strategic approach to managing payables that might also strengthen supplier relationships. The fluctuation around 2021 suggests a potential period of financial adjustment or external pressures impacting payment patterns. The subsequent recovery and improvement point to operational resilience and enhanced working capital management in recent periods.
Cash Conversion Cycle
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data | ||||||||||||||||||||||||||||||
Average inventory processing period | 94 | 101 | 102 | 112 | 106 | 104 | 95 | 83 | 79 | 73 | 71 | 72 | 68 | 76 | 66 | 62 | 54 | 49 | 45 | 39 | — | — | — | |||||||
Average receivable collection period | 87 | 89 | 87 | 84 | 81 | 85 | 86 | 83 | 83 | 85 | 93 | 97 | 100 | 80 | 81 | 83 | 85 | 87 | 84 | 81 | — | — | — | |||||||
Average payables payment period | 32 | 36 | 43 | 42 | 46 | 49 | 64 | 59 | 67 | 92 | 59 | 73 | 66 | 55 | 39 | 48 | 36 | 38 | 41 | 45 | — | — | — | |||||||
Short-term Activity Ratio | ||||||||||||||||||||||||||||||
Cash conversion cycle1 | 149 | 154 | 146 | 154 | 141 | 140 | 117 | 107 | 95 | 66 | 105 | 96 | 102 | 101 | 108 | 97 | 103 | 98 | 88 | 75 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||||
Abbott Laboratories | 114 | 110 | 103 | 82 | 82 | 85 | 77 | 70 | 80 | 84 | 90 | 94 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Intuitive Surgical Inc. | 203 | 183 | 187 | 190 | 176 | 161 | 161 | 147 | 146 | 151 | 165 | 181 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Medtronic PLC | 182 | 171 | 157 | 148 | 153 | 149 | 147 | 143 | 165 | 166 | 172 | 146 | — | — | — | — | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q3 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 94 + 87 – 32 = 149
2 Click competitor name to see calculations.
- Average inventory processing period
- The average inventory processing period shows a generally increasing trend over the analyzed timeframe. Starting from 39 days in March 2019, it rises steadily with some fluctuations, peaking at 112 days in March 2023 before slightly declining to 101 and 94 days in the most recent quarters. This indicates a lengthening in the time inventory remains before being processed, potentially suggesting slower turnover or increased inventory holdings.
- Average receivable collection period
- The average receivable collection period remains relatively stable over the periods, generally fluctuating between the low 80s and high 80s number of days. There is a noticeable spike to 100 days in December 2020, after which it decreases and stabilizes around the mid-80s. This stability suggests consistent credit and collection practices, though the peak in late 2020 may reflect temporary collection challenges.
- Average payables payment period
- The average payables payment period fluctuates with some variability during the timeframe. It initially decreases from 45 days in March 2019 to as low as 36 days in December 2019, then exhibits significant increases and decreases including a spike to 92 days in March 2021, followed by a gradual decline to 32 days by September 2023. This volatility may indicate changes in payment policies or supplier negotiations affecting the timing of liabilities settlement.
- Cash conversion cycle
- The cash conversion cycle (CCC) shows an overall upward trend, indicating lengthening time between cash outflows and inflows. Starting at 75 days in March 2019, the CCC rises quite steadily with some variability, reaching a high point of 154 days in September 2023, though slight decreases appear in interim quarters. The increase is driven mainly by the extension of the inventory processing period and fluctuating payables payment terms. This suggests a growing capital tied up in operations and potential liquidity risks.